# Contraline

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/contraline

- Industry: Biotechnology
- Headquarters: Charlottesville, US
- Website: www.contraline.com
- Total disclosed funding: $75M
- Latest round: Series B (May 29, 2026)
- Investors on record: 28

## About

Contraline, Inc. focuses on pioneering male contraceptive solutions, particularly with its flagship product ADAM™, designed as a long-lasting implant that enhances reproductive autonomy for men.Founded in 2015 and headquartered in Charlottesville, US, Contraline, Inc. specializes in male contraceptive solutions. In June 2026, Contraline, Inc. raised USD 92.5 million in series B funding co-led by BVF Partners and RA Capital Management, with participation from Lumira Ventures and Invus Financial Advisors, and GV. CEO Kevin Eisenfrats, who is also the founder, has been integral to the company's strategic vision and development of its innovative products.Contraline specializes in innovative contraceptive solutions, primarily focusing on the development of ADAM™, the first long-lasting implant designed for male contraception. This product functions similarly to intrauterine devices (IUDs) used by women, providing a reversible and effective form of birth control specifically for men. The company's mission is to resolve the limitations faced by traditional contraceptive methods, aiming to enhance user experience. Target customers include men seeking reliable contraceptive options, healthcare providers, and family planning organizations in North America and Europe.Contraline's revenue model is based on direct-to-consumer sales and partnerships with healthcare providers and family planning clinics. The company generates income through sales of its flagship product, ADAM™, and may also engage in institutional agreements with clinics offering reproductive health services. Though specific pricing plans for ADAM™ are not disclosed, the company's strategy emphasizes direct engagement with end-users to enhance accessibility and adoption of its innovative solution. The company plans to use the June 2026 funding to support the late-stage development of its NES/T Gel male contraceptive and other pipeline assets.

## Funding rounds

- Series B, May 29, 2026, $56M — MVM Partners, Gates Foundation Trust, Venrock, Adage Capital Management, Forbion, GV, Invus Financial Advisors, BVF Partners, RA Capital Management, Milky Way Ventures, ShangBay Capital, Xuanzhu Biopharmaceutical Co., Ltd., Lumira Ventures
- Series A, Oct 20, 2021, $11M — Founders Fund, Graphene Ventures, ShangBay Capital, Rhia Ventures, Metaplanet Holdings, MBX Capital, Amboy Street Ventures, Smith Ventures
- Series A, Oct 31, 2020, $6M — Graphene Ventures, Bioverge, Metaplanet Holdings, Beni Venture Capital, MBX Capital
- Series A, Apr 4, 2020 — Venture University Venture Partners, VU Venture Partners
- Seed, Mar 31, 2017, $2.3M — Founders Fund, Virginia Venture Partners, Afton Scientific, LLC, Abstract Ventures
- Seed, Jun 1, 2016, $0.7M — Kima Ventures, Afton Scientific, LLC

## Investors

- Kima Ventures (https://capitalatlas.ai/funds/kima-ventures) — Seed
- Afton Scientific, LLC — Seed
- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Seed, Series A
- Virginia Venture Partners (https://capitalatlas.ai/funds/virginia-venture-partners) — Seed
- Abstract Ventures (https://capitalatlas.ai/funds/abstract-ventures) — Seed
- Venture University Venture Partners (https://capitalatlas.ai/funds/venture-university-venture-partners) — Series A
- VU Venture Partners (https://capitalatlas.ai/funds/vu-venture-partners) — Series A
- Graphene Ventures (https://capitalatlas.ai/funds/graphene-ventures) — Series A
- Bioverge (https://capitalatlas.ai/funds/bioverge) — Series A
- Metaplanet Holdings (https://capitalatlas.ai/funds/metaplanet-holdings) — Series A
- Beni Venture Capital (https://capitalatlas.ai/funds/beni-venture-capital) — Series A
- MBX Capital (https://capitalatlas.ai/funds/mbx-capital) — Series A
- ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series A, Series B
- Rhia Ventures (https://capitalatlas.ai/funds/rhia-ventures) — Series A
- Amboy Street Ventures (https://capitalatlas.ai/funds/amboy-street-ventures) — Series A
- Smith Ventures (https://capitalatlas.ai/funds/smith-ventures) — Series A
- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Series B
- Gates Foundation Trust — Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B
- Adage Capital Management — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Milky Way Ventures (https://capitalatlas.ai/funds/milky-way-ventures) — Series B
- Xuanzhu Biopharmaceutical Co., Ltd. — Series B
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series B